Results for “chemotherapy”
Paul Ehrlich
Paul Ehrlich (1854-1915) was a German physician-scientist who founded modern immunology and chemotherapy, earning the 1908 Nobel Prize for his “magic bullet” concept that led to the first cure for syphilis.
Health & MedicineBrain Tumors
Brain tumors are abnormal growths of cells within the brain that can be either malignant (cancerous) or benign (non-cancerous), leading to a range of symptoms and potential complications. ## Overview Brain tumors are a complex and multifaceted medical condition that affects millions of people worldwide. A brain tumor occurs when a group of cells within the brain grow out of control, creating a mass that can interfere with the normal functioning of the brain. There are two main types of tumors: malignant (cancerous) tumors and benign (non-cancerous) tumors. Malignant tumors are more aggressive and can spread to other parts of the brain or body, while benign tumors are typically slower-growing and less likely to spread. Brain tumors can be further classified as primary tumors, which start within the brain, and secondary tumors, which most commonly have spread from tumors located outside the brain, known as brain metastasis tumors. Primary brain tumors can arise from various types of brain cells, including neurons, glial cells, and blood vessels. Secondary brain tumors, on the other hand, are typically metastases from cancers that have spread from other parts of the body, such as the lungs, breast, or skin. Symptoms of brain tumors can vary depending on the size of the tumor and the part of the brain that is involved. Common symptoms include headaches, seizures, problems with vision, vomiting, and mental changes. Other symptoms may include difficulty walking, speaking, with sensations, or unconsciousness. In some cases, brain tumors may not produce any noticeable symptoms until they have grown significantly. ## History/Background The concept of brain tumors dates back thousands of years, with ancient civilizations such as the Egyptians and Greeks describing cases of brain tumors. However, it wasn't until the late 19th century that the first modern descriptions of brain tumors were made by physicians such as William Gowers and Harvey Cushing. Cushing, in particular, made significant contributions to the field of neurosurgery and was one of the first physicians to develop techniques for removing brain tumors. In the early 20th century, the development of imaging technologies such as X-rays and computed tomography (CT) scans revolutionized the diagnosis and treatment of brain tumors. Today, advanced imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans are used to diagnose and monitor brain tumors. ## Key Information * **Types of Brain Tumors**: There are over 120 different types of brain tumors, including gliomas, meningiomas, and acoustic neuromas. * **Causes and Risk Factors**: The exact causes of brain tumors are not fully understood, but risk factors include genetic mutations, exposure to radiation, and certain environmental toxins. * **Symptoms**: Common symptoms of brain tumors include headaches, seizures, problems with vision, vomiting, and mental changes. * **Diagnosis**: Brain tumors are typically diagnosed using imaging technologies such as MRI and CT scans. * **Treatment**: Treatment options for brain tumors include surgery, radiation therapy, and chemotherapy. * **Prognosis**: The prognosis for brain tumors varies depending on the type and location of the tumor, as well as the patient's overall health. ## Significance Brain tumors are a significant public health concern, with over 80,000 new cases diagnosed in the United States each year. Brain tumors can have a profound impact on patients and their families, causing significant emotional, physical, and financial burdens. However, advances in medical technology and treatment options have improved the prognosis for many patients with brain tumors. INFOBOX: - Name: Brain Tumors - Type: Medical Condition - Date: Ancient civilizations (descriptions of brain tumors date back thousands of years) - Location: Brain - Known For: Complex and multifaceted medical condition that affects millions of people worldwide TAGS: brain tumors, cancer, neurology, neurosurgery, medical imaging, radiation therapy, chemotherapy, prognosis, public health.
Health & MedicineLymphoma
** Lymphoma is a group of malignant cancers that arise from lymphocytes, the white‑blood cells that orchestrate the body’s immune response. **CONTENT:** ## Overview Lymphoma encompasses a heterogeneous collection of **blood and lymphatic system tumors** that originate from **B‑cells or T‑cells**, the two main types of lymphocytes. Although the term “lymphoma” can technically describe any abnormal growth of lymphoid tissue, in clinical practice it is reserved for the **cancerous** forms that spread through the lymphatic network, blood, and sometimes other organs. The disease is broadly divided into **Hodgkin lymphoma (HL)**, characterized by the presence of Reed‑Sternberg cells, and **non‑Hodgkin lymphoma (NHL)**, a diverse group that accounts for roughly 85 % of all cases. Patients often present with **painless, enlarged lymph nodes**, most commonly in the neck, armpits, or groin. Systemic “B‑symptoms”—fever, drenching night sweats, and unintended weight loss—signal a more aggressive disease course. Additional complaints may include **pruritus (itching)**, persistent fatigue, and, in advanced stages, organ‑specific symptoms such as abdominal pain from splenomegaly or shortness of breath from mediastinal masses. Because early signs can mimic benign infections, a high index of suspicion and prompt diagnostic work‑up are essential. ## History/Background The first documented description of a lymphoma‑like disease dates to **1845**, when Thomas Hodgkin reported a case of “a disease of the lymphatic system” in a young man with enlarged cervical nodes. The eponymous **Hodgkin lymphoma** was formally named after him in the early 20th century. In the 1950s, the **Rappaport classification** introduced a histologic framework that distinguished between Hodgkin and non‑Hodgkin types, paving the way for modern taxonomy. The **1970s and 1980s** saw the advent of combination chemotherapy (e.g., CHOP) and the first **monoclonal antibody therapy** (rituximab) for B‑cell NHL, dramatically improving survival. Ongoing research into **genomic profiling** and **immune checkpoint inhibition** continues to refine treatment paradigms. ## Key Information - **Epidemiology:** Approximately 9 % of all cancers worldwide are lymphomas, with an incidence of ~5 per 100,000 persons annually in high‑income nations. HL shows a bimodal age distribution (young adults and >55 years), whereas NHL incidence rises steadily with age. - **Risk Factors:** Immunosuppression (HIV, organ transplantation), chronic infections (EBV, H. pylori, HTLV‑1), certain autoimmune diseases, and exposure to chemicals (pesticides, benzene) increase risk. - **Diagnosis:** Core components include **excisional lymph node biopsy**, immunophenotyping (flow cytometry), cytogenetic studies, and imaging (PET‑CT). Staging follows the **Ann Ann Arbor system**, incorporating the number of involved sites and presence of B‑symptoms. - **Treatment:** Therapeutic strategies are tailored to subtype, stage, and patient factors. First‑line regimens range from **ABVD** for early‑stage HL to **R‑CHOP** for many B‑cell NHLs. Advanced or refractory disease may require **high‑dose chemotherapy with autologous stem‑cell rescue**, **CAR‑T cell therapy**, or **immune checkpoint inhibitors** (e.g., pembrolizumab). - **Prognosis:** Five‑year survival exceeds 85 % for early‑stage HL but varies widely for NHL (from >90 % for indolent follicular lymphoma to <30 % for aggressive peripheral T‑cell lymphomas). **When to seek professional care:** Any persistent, painless swelling of lymph nodes lasting more than two weeks, unexplained fever, night sweats, weight loss, or ongoing fatigue warrants evaluation by a healthcare professional. Early diagnosis improves treatment options and outcomes. ## Significance Lymphoma’s impact extends beyond individual patients; it drives advances in **cancer biology, immunology, and targeted therapy**. The success of **rituximab**, the first monoclonal antibody approved for cancer, sparked a wave of biologic agents now standard across oncology. Moreover, lymphoma research has illuminated mechanisms of **immune evasion**, informing the development of **checkpoint inhibitors** that benefit a broad spectrum of malignancies. From a public‑health perspective, survivorship programs address long‑term effects such as secondary malignancies, cardiovascular disease, and psychosocial challenges, underscoring the need for comprehensive, multidisciplinary care. **INFOBOX:** - Name: Lymphoma (Hodgkin and Non‑Hodgkin) - Type: Malignant neoplasm of lymphoid tissue - Date: First described 1845 (Hodgkin’s disease) - Location: Primarily lymph nodes; may involve spleen, bone marrow, extranodal sites - Known For: Pioneering use of monoclonal antibodies and CAR‑T cell therapy in cancer treatment **TAGS:** lymphoma, Hodgkin lymphoma, non‑Hodgkin lymphoma, oncology, immunotherapy, chemotherapy, hematology, cancer research
Health & MedicineChemotherapy
Chemotherapy is a systemic cancer treatment that uses anti‑cancer drugs, alone or in combination, to kill or control malignant cells.
Health & MedicinePancreatic Cancer
** Pancreatic cancer is a malignant disease that originates in the pancreas, a deep‑lying gland that produces digestive enzymes and hormones, and is characterized by aggressive growth, early metastasis, and a high mortality rate. **CONTENT:** ## Overview The pancreas sits retroperitoneally behind the stomach and serves both exocrine (digestive enzyme) and endocrine (insulin, glucagon) functions. **Pancreatic cancer** occurs when genetic and environmental insults cause pancreatic cells to proliferate uncontrollably, forming a tumor that can invade surrounding tissues and spread through the bloodstream or lymphatic system. The most common histologic type is **pancreatic ductal adenocarcinoma (PDAC)**, accounting for roughly 85 % of cases; other, rarer forms include **neuroendocrine tumors**, **acinar cell carcinoma**, and **intrapancreatic mucinous cystic neoplasms**. Because the organ is deep within the abdomen, early tumors are often asymptomatic, and when symptoms such as jaundice, weight loss, or new‑onset diabetes appear, the disease is frequently already advanced. Diagnosis relies on a combination of imaging (contrast‑enhanced CT, MRI, endoscopic ultrasound), tissue sampling (fine‑needle aspiration), and tumor markers such as **CA 19‑9**. Treatment options are stage‑dependent: surgical resection (most commonly a Whipple pancreaticoduodenectomy) offers the only potential cure, while chemotherapy (e.g., gemcitabine ± nab‑paclitaxel) and radiation provide palliation and modest survival benefits for unresectable disease. Multidisciplinary care—including oncology, surgery, gastroenterology, nutrition, and palliative services—is essential. **Patients experiencing unexplained abdominal pain, persistent jaundice, or rapid weight loss should seek prompt medical evaluation**, as early detection dramatically influences outcomes. ## History/Background The first recorded description of a pancreatic tumor dates to the 19th century, when German pathologist **Rudolf Virchow** identified malignant growths in autopsy specimens. Surgical attempts began in the early 1900s, but high peri‑operative mortality limited progress. A landmark breakthrough occurred in 1935 when **Allen Whipple** performed the first successful pancreaticoduodenectomy, now known as the **Whipple procedure**, establishing a surgical foundation still used today. The advent of **computed tomography (CT)** in the 1970s and **magnetic resonance imaging (MRI)** in the 1980s revolutionized staging, while the discovery of the **KRAS** oncogene mutation in the 1980s provided a molecular foothold for research. In the 1990s, the FDA approved **gemcitabine**, the first chemotherapy agent shown to modestly extend survival, and the 2000s saw the integration of combination regimens and targeted therapies, though overall cure rates remain low. ## Key Information - **Epidemiology:** Pancreatic cancer is the 7th leading cause of cancer death worldwide, with an incidence of ~13 per 100,000 people in high‑income nations; incidence rises sharply after age 60. - **Risk factors:** Tobacco smoking, chronic pancreatitis, hereditary syndromes (e.g., BRCA2, PALB2, Lynch syndrome), obesity, and long‑standing diabetes increase risk. - **Staging:** The AJCC 8th edition uses a TNM system; stage I disease is confined to the pancreas, while stage IV indicates distant metastasis. - **Biomarkers:** **CA 19‑9** is the most widely used serum marker for monitoring response, though it lacks sensitivity for early detection; emerging markers include circulating tumor DNA and exosomal proteins. - **Treatment milestones:** * **Surgery:** Whipple procedure, distal pancreatectomy, and total pancreatectomy. * **Chemotherapy:** Gemcitabine, FOLFIRINOX (5‑FU, leucovorin, irinotecan, oxaliplatin), and nab‑paclitaxel combinations. * **Targeted therapy:** PARP inhibitors for BRCA‑mutated tumors; immune checkpoint inhibitors for microsatellite‑instable (MSI‑H) cancers. - **Prognosis:** Median overall survival remains ~12 months for all stages combined; five‑year survival is <10 % in the United States. Early‑stage resected disease can achieve 20–30 % five‑year survival. ## Significance Pancreatic cancer’s lethality underscores a critical public‑health challenge: the need for better screening, earlier diagnosis, and more effective therapies. Its biology—marked by dense stromal desmoplasia, early metastatic spread, and resistance to conventional cytotoxics—has driven innovative research into tumor microenvironment modulation, organoid modeling, and precision genomics. Successful breakthroughs could transform not only pancreatic oncology but also provide insights applicable to other fibrotic, treatment‑resistant cancers. Moreover, the disease’s impact extends beyond mortality; patients often endure severe pain, nutritional deficiencies, and psychological distress, highlighting the importance of comprehensive palliative care. Continued investment in multidisciplinary research, public awareness of risk factors, and equitable access to high‑volume surgical centers are essential to improve outcomes and reduce the global burden of this formidable malignancy. **INFOBOX:** - Name: Pancreatic Cancer - Type: Malignant neoplasm of the pancreas (primarily ductal adenocarcinoma) - Date: First surgical resection (Whipple procedure) performed in 1935; modern multimodal therapy evolving since the 1990s - Location: Pancreas (retroperitoneal organ behind the stomach) - Known For: Aggressive biology, low early‑detection rates, and being a leading cause of cancer mortality **TAGS:** pancreatic cancer, ductal adenocarcinoma, oncology, surgery, chemotherapy, genetics, biomarkers, palliative care